Cybin Inc. to Present at H.C. Wainwright Global Investment Conference

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:00 a.m. ET. This presentation provides an important platform for the company to discuss its innovative approach to mental healthcare and its pipeline of next-generation treatments.

The company's participation in this prestigious investment conference underscores the significant financial and clinical interest in novel mental health treatments. Cybin is developing CYB003, a proprietary deuterated psilocin analog that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is currently in Phase 3 studies for adjunctive treatment of major depressive disorder. Additionally, the company is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.

For investors and stakeholders seeking additional information, the latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN. The full press release detailing the conference participation can be viewed at https://ibn.fm/jkHN9. These developments represent important milestones in the mental health treatment landscape, particularly given the large unmet need for effective and durable treatment options for mental health conditions.

The company's research pipeline includes investigational compounds focused on 5-HT receptors, positioning Cybin at the forefront of neuropsychiatry innovation. Founded in 2019, Cybin maintains operations in Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to addressing mental health challenges. The presentation at the H.C. Wainwright conference provides an opportunity for the investment community to gain deeper insights into the company's progress and future direction in developing breakthrough mental health treatments.